Term
| improved mood, modulation of anxiety, sleep regulation, appetite regulation, body temp regulation |
|
Definition
|
|
Term
| improved mood; fight or flight; mental organization; rewards; cardiovascular |
|
Definition
|
|
Term
| improved mood; psychosis; attention/cognition; reward/reinforcement of pleasure; motor function |
|
Definition
|
|
Term
| Urinary retention; dry mouth, constipation; tachycardia; learning; muscle action |
|
Definition
| Acetylcholine (ACH)- antagonism |
|
|
Term
|
Definition
| Histamine (H1)- antagonism |
|
|
Term
| antidepressant groups usedi n treating depression and anxiety |
|
Definition
| selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitions (SNRIs); monamine oxidase inhibitors (MOIs); atypical antidepressants |
|
|
Term
| not as selective as you think they are! |
|
Definition
| selective serotonin reuptake inhibitors |
|
|
Term
| Fluoxetine (Prozac); Sertraline (Zoloft); Fluvoxamine (Oluvox); Citalopram (Celexa); Escitalopram (Lexapro); Paroxetine (Paxil) |
|
Definition
|
|
Term
| has an active and inactive isomer; modulates the anxiety it causes; an SSRI he uses |
|
Definition
|
|
Term
| has an active and inactive isomer; modulates the anxiety it causes; an SSRI he uses |
|
Definition
|
|
Term
| Should be discontinued in the U.S. like it is in the U.K (SSRI) |
|
Definition
|
|
Term
| anxiety, agitation, akathisia, panic, insomnia, sexual dysfunction, hyponatremia, decrease in platelet aggregation; bleeding risk |
|
Definition
|
|
Term
| Amitriptyline, Clomipramine, Desimpramine, Doxepin, Duloxetie, Imipramine, Nortriptyline, Venlafaxine/desvenlafaxine |
|
Definition
|
|
Term
| shouldn't use... takes care of the depression but doesn't solve their anxiety. terrible withdrawal (SNRI) |
|
Definition
| Venlafaxine/desvenlafaxine (Effexor/Pristiq) |
|
|
Term
| brought on the market for neuropathy, has been okayed for depression; expensive; dose is not strong enough (SNRI) |
|
Definition
|
|
Term
| severe sedation; constipation; weight gain; cardiovascular; orthostatic hypotension; sexual dysfunction; insomnia; sweating; tremors |
|
Definition
|
|
Term
| Phenelzine (Nardil); Tranylcyromine (parnate); Selegiline (Eldepryl) |
|
Definition
| Monamine Oxidase Inhibitors (MAOIs) |
|
|
Term
| orthostatic hypertension; drowsins; constipation; tremors; hypertensive crisis; anxiety |
|
Definition
|
|
Term
| have to be very careful with diet; a lot of interactions with these drugs |
|
Definition
|
|
Term
| inhibits reuptake of serotonin and norepinephrine; 5HT-2 and alpha1 receptor antagonists --- not used anymore because of liver failure |
|
Definition
|
|
Term
| somnolence, dizziness, constipation, orthostatic hypotension, liver failure (rare, 1 in 250,000-300,000) |
|
Definition
|
|
Term
| inhibits reuptake of serotonin, histamine, alpha1-adrenergic receptor antagonists |
|
Definition
|
|
Term
| blurred vision, dizziness, dry mouth, nasal congestion, priaprism; used mainly for side effect (drowsiness) |
|
Definition
|
|
Term
| blocks reuptake of norepinephrine and dopamine |
|
Definition
|
|
Term
| used for depression, smoking deterrent, ADHD; Adverse events: headache, dry mouth, weight loss, insomnia, agitation/anxiety |
|
Definition
|
|
Term
| presynaptic alpha2 antagonist effects stimulates norepinephrine and serotonin release; potent antagonist of 5HT2, 5HT3 and histamine receptors |
|
Definition
|
|
Term
| somnolence, weight gain, increased appetite, constipation, xerostomia |
|
Definition
| mirtazapine (remeron) adverse effects |
|
|
Term
| selective serotonin reuptake inhibitor and partial agonist of 5HT1A receptors (exact MOA is not entirely known) |
|
Definition
|
|
Term
| GI-- diarrhea, nausea; neurological- dizziness, insomnia; cardiovascular- palpitations, ventricular premature beats |
|
Definition
| Vilazodone adverse effects |
|
|
Term
| decreased anxiety; improved sleep; improved appetite |
|
Definition
| first week (symptom remission) |
|
|
Term
| increased activities; sex drive, self-care, memory; thinking and movement normalizing; sleeping and eating patterns normalizing |
|
Definition
|
|
Term
| relief of depressed mood; less hopelessness and helplessness; thoughts of suicide subside |
|
Definition
|
|
Term
| no symptoms or significant reduction in depressive symptoms for at least 2 weeks |
|
Definition
|
|
Term
| a period of 2 weeks and <2 months with no or few depressive symptoms |
|
Definition
|
|
Term
| absence of significant symptoms of depression (e.g. no more than 1-2 symptoms for 2 months) |
|
Definition
|
|
Term
| relapse a DSM episode of depression during the period of remission |
|
Definition
|
|
Term
| emergence of symptoms of depression during the period of recovery (a new episode) |
|
Definition
|
|
Term
| continuation of treatment |
|
Definition
| recommended for at least 6-12 months for all responders to acute treatment |
|
|
Term
| lack of patient education with medication; choice of medication prescribed; understanding possible side effect issues: activation, insomnia, akathisia |
|
Definition
| possible mechanism for suicide |
|
|
